The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Open accessAbstract
Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationMorgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 201–300 of 1,006
Jain, T., Knežević, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M. M., Shah, G. L., Halton, E. F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002509 · Cited by 277
Batra, S. A., Rathi, P., Guo, L., Courtney, A. N., Fleurence, J., Balzeau, J. C., Shaik, R. S., Nguyen, T. P., Wu, M., Bulsara, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0293 · Cited by 278
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2016) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 271
Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al‐Homsi, A. S., et al. (2016) · The Prostate · doi:10.1002/pros.23214 · Cited by 267
Jeha, S., Pei, D., Choi, J. K., Cheng, C., Sandlund, J. T., Coustan‐Smith, E., Campana, D., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01692 · Cited by 273
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Gust, J., Taraseviciute, A., & Turtle, C. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0582-9 · Cited by 267
Cytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R. A., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 279
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Yu, S., Yi, M., Qin, S., & Wu, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1057-4 · Cited by 269
Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., Gu, C., Zhang, S., Chen, L., Cheng, J., et al. (2019) · Blood · doi:10.1182/blood.2019000017 · Cited by 263
Sheih, A., Voillet, V., Hanafi, L., DeBerg, H. A., Yajima, M., Hawkins, R. M., Gersuk, V. H., Riddell, S. R., Maloney, D. G., Wohlfahrt, M. E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13880-1 · Cited by 268
Schneider, D., Xiong, Y., Wu, D., Nölle, V., Schmitz, S. M., Haso, W. M., Kaiser, A., Dropulić, B., & Orentas, R. J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0246-1 · Cited by 267
Self-citationNovel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 264
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 264
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R. A., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez‐Cuyar, L. F., Baldessari, A. E., English, C. N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 261
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Harris, D. T., & Kranz, D. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.004 · Cited by 262
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Rubin, D. B., Danish, H. H., Ali, A. B., Li, K., LaRose, S. L., Monk, A. D., Coté, D. J., Spendley, L. N., Kim, A. H., Robertson, M. S., et al. (2019) · Brain · doi:10.1093/brain/awz053 · Cited by 260
Ji, H., Hu, C., Yang, X., Liu, Y., Ji, G., Ge, S., Wang, X., & Wang, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01576-4 · Cited by 279
Diaconu, I., Ballard, B. C., Zhang, M., Chen, Y., West, J., Dotti, G., & Savoldo, B. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.011 · Cited by 257
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Lin, A. W., Vandris, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01960-7 · Cited by 253
Self-citationBoyiadzis, M. M., Dhodapkar, M. V., Brentjens, R. J., Kochenderfer, J. N., Neelapu, S. S., Maus, M. V., Porter, D. L., Maloney, D. G., Grupp, S. A., Mackall, C. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0460-5 · Cited by 255
Self-citationThe application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., & Wu, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.03.001 · Cited by 261
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Cartellieri, M., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Ehninger, A., Bonin, M. V., Bejestani, E. P., Ehninger, G., & Bachmann, M. P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.61 · Cited by 255
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 246
Kuhn, N. F., Purdon, T. J., van Leeuwen, D. G., Lopez, A. V., Curran, K. J., Daniyan, A. F., & Brentjens, R. J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.006 · Cited by 255
Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 244
Self-citationGenetically engineered T cells for cancer immunotherapy
Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0070-9 · Cited by 255
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Pan, J., Niu, Q., Deng, B., Liu, S., Wu, T., Gao, Z., Liu, Z., Zhang, Y., Qu, X., Zhang, Y., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0488-7 · Cited by 245
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M. E., & de Miranda, N. F. C. C. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 244
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Mahadeo, K. M., Khazal, S. J., Abdel‐Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D. C., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0075-2 · Cited by 246
Pharmacologic control of CAR-T cell function using dasatinib
Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028720 · Cited by 246
Self-citationCRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., & Wang, H. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0543-6 · Cited by 239
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Liu, G., Rui, W., Zhao, X., & Lin, X. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00655-2 · Cited by 244
Pan, J., Yang, J., Deng, B., Zhao, X. J., Zhang, X., Lin, Y., Wu, Y., Deng, Z. L., Zhang, Y. L., Liu, S. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.145 · Cited by 233
Wang, Y., Tong, C., Dai, H., Wu, Z., Han, X., Guo, Y., Chen, D., Wei, J., Ti, D., Liu, Z. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20696-x · Cited by 241
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 249
Chimeric antigen receptor T cell therapy: 25years in the making
Gill, S. I., Maus, M. V., & Porter, D. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.10.003 · Cited by 245
Clinical development of gene therapy: results and lessons from recent successes
Kumar, S. R. P., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 246
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Monje, M., Mahdi, J., Majzner, R. G., Yeom, K. W., Schultz, L. M., Richards, R. M., Barsan, V. V., Song, K.-W., Kamens, J. L., Baggott, C., et al. (2024) · Nature · doi:10.1038/s41586-024-08171-9 · Cited by 248
Self-citationCAR therapy: the CD19 paradigm
Sadelain, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80010 · Cited by 238
Klebanoff, C. A., Crompton, J. G., Leonardi, A. J., Yamamoto, T. N., Chandran, S. S., Eil, R. L., Sukumar, M., Vodnala, S. K., Hu, J., Ji, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.95103 · Cited by 231
Self-citationCAR T cells for infection, autoimmunity and allotransplantation
Maldini, C. R., Ellis, G. I., & Riley, J. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0042-2 · Cited by 230
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Sheth, V., & Gauthier, J. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01134-4 · Cited by 244
Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J. E., Stefanski, H. E., Talano, J.-A., Moskop, A. M., Margossian, S. P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03585 · Cited by 236
Self-citationMyers, R. M., Taraseviciute, A., Steinberg, S. M., Lamble, A. J., Sheppard, J., Yates, B., Kovach, A. E., Wood, B., Borowitz, M. J., Stetler-Stevenson, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01405 · Cited by 225
Self-citationCytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Frey, N. V., & Porter, D. L. (2016) · Hematology · doi:10.1182/asheducation-2016.1.567 · Cited by 222
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
Sommermeyer, D., Hill, T. J., Shamah, S. M., Salter, A. I., Chen, Y., Mohler, K., & Riddell, S. R. (2017) · Leukemia · doi:10.1038/leu.2017.57 · Cited by 224
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Labanieh, L., Majzner, R. G., Klysz, D. D., Sotillo, E., Fisher, C., Vilches-Moure, J. G., Pacheco, K. Z., Malipatlolla, M. B., Xu, P., Hui, J. H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.041 · Cited by 232
Self-citationChimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 222
Ghosh, A., Smith, M. M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., Gunset, G., Perna, F., Kreines, F. M., Levy, E. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4258 · Cited by 217
Freyer, C. W., & Porter, D. L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.025 · Cited by 216
Principles of adoptive T cell therapy in cancer
Met, Ö., Mølgaard, K., Chamberlain, C. A., Donia, M., & Svane, I. M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 219
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Upadhyay, R., Boiarsky, J., Pantsulaia, G., Svensson‐Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A. I., Rossi, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0756 · Cited by 216
Zhou, X., Dotti, G., Krance, R. A., Martinez, C. A., Naik, S., Kamble, R. T., Durett, A. G., Dakhova, O., Savoldo, B., Stasi, A. D., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628354 · Cited by 216
Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
Wang, D., Starr, R., Chang, W.-C., Aguilar, B., Alizadeh, D., Wright, S. L., Yang, X., Brito, A., Sarkissian, A., Ostberg, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2672 · Cited by 220
CAR T‐Cell‐Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Jogalekar, M. P., Rajendran, R. L., Khan, F., Dmello, C., Gangadaran, P., & Ahn, B.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925985 · Cited by 214
Zhang, X., Lu, X., Yang, J., Zhang, G., Li, J., Song, L., Su, Y., Shi, Y., Zhang, M., He, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001466 · Cited by 220
CAR T cells for brain tumors: Lessons learned and road ahead
Akhavan, D., Alizadeh, D., Wang, D., Weist, M. R., Shepphird, J. K., & Brown, C. E. (2019) · Immunological Reviews · doi:10.1111/imr.12773 · Cited by 217
Chimeric antigen receptor T-cell therapies for multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2017) · Blood · doi:10.1182/blood-2017-06-793869 · Cited by 216
Self-citationHow I treat relapsed acute lymphoblastic leukemia in the pediatric population
Hunger, S. P., & Raetz, E. A. (2020) · Blood · doi:10.1182/blood.2019004043 · Cited by 219
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Yang, Y., Kohler, M. E., Chien, C. D., Sauter, C. T., Jacoby, E., Yan, C., Hu, Y., Wanhainen, K., Qin, H., & Fry, T. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1209 · Cited by 208
Self-citationBioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Agarwalla, P., Ogunnaike, E. A., Ahn, S., Froehlich, K. A., Jansson, A., Ligler, F. S., Dotti, G., & Brudno, Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01245-x · Cited by 216
Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Himeles, J. R., Arnam, J. V., Melenhorst, J. J., Mohan, D., DiNofia, A. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000692 · Cited by 210
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Leahy, A. B., Callahan, C. A., Dolan, J. G., Fitzgerald, J. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02477 · Cited by 208
Wang, D., Wang, J., Hu, G., Wang, W., Xiao, Y., Cai, H., Jiang, L., Li, M., Yang, Y., Zhou, X., et al. (2021) · Blood · doi:10.1182/blood.2020008936 · Cited by 210
Designing chimeric antigen receptors to effectively and safely target tumors
Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 207
Chen, Y., Sun, C., Landoni, E., Metelitsa, L. S., Dotti, G., & Savoldo, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1811 · Cited by 208
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Chong, E. A., Alanio, C., Svoboda, J., Nasta, S. D., Landsburg, D. J., Lacey, S. F., Ruella, M., Bhattacharyya, S., Wherry, E. J., & Schuster, S. J. (2021) · Blood · doi:10.1182/blood.2021012634 · Cited by 209
Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety
Nguyen, N. T., Huang, K., Zeng, H., Ji, J., Wang, R. Y., Fang, S., Chen, J., Liu, X., Huang, Z., You, M. J., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00982-5 · Cited by 215
Sarhan, D., Cichocki, F. M., Zhang, B., Yingst, A. M., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 198
Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges
Cavazzana, M., Bushman, F. D., Miccio, A., André‐Schmutz, I., & Six, E. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0020-9 · Cited by 205
Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O’Dwyer, K. M., Holmes, H. E., Arellano, M. L., Ghobadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020009098 · Cited by 209
Nakagawara, A., Li, Y., Izumi, H., Muramori, K., Inada, H., & Nishi, M. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx176 · Cited by 204
Miller, J. S., Morishima, C., McNeel, D. G., Patel, M. R., Kohrt, H. E. K., Thompson, J. A., Sondel, P. M., Wakelee, H. A., Disis, M. L., Kaiser, J. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2451 · Cited by 203
Impact of Manufacturing Procedures on CAR T Cell Functionality
Watanabe, N., Mo, F., & McKenna, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876339 · Cited by 206
Yan, T., Zhu, L., & Chen, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00373-7 · Cited by 209
Yang, P., Song, H., Qin, Y., Huang, P., Zhang, C., Kong, D., & Wang, W. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01406 · Cited by 197
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
Singh, N., Frey, N. V., Engels, B., Barrett, D. M., Shestova, O. E., Ravikumar, P., Cummins, K. D., Lee, Y. G., Pajarillo, R., Chun, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01326-5 · Cited by 199
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z. J., Spiegel, J. Y., Craig, J. K., Claire, G. K., Frank, M. J., Muffly, L. S., Shiraz, P., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002732 · Cited by 200
Self-citationGamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Saura‐Esteller, J., de Jong, M., King, L. A., Ensing, E., Winograd, B., de Gruijl, T. D., Parren, P. W. H. I., & van der Vliet, H. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915837 · Cited by 210
Cell-based therapy technology classifications and translational challenges
Mount, N. M., Ward, S., Kefalas, P., & Hyllner, J. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2015.0017 · Cited by 203
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Zhang, E., & Xu, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0379-6 · Cited by 196
Scarfò, I., & Maus, M. V. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0230-9 · Cited by 195
Ruella, M., Klichinsky, M., Kenderian, S. S., Shestova, O. E., Ziober, A. F., Kraft, D. O., Feldman, M. D., Wasik, M. A., June, C. H., & Gill, S. I. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0850 · Cited by 197
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Hunter, B. D., & Jacobson, C. A. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz017 · Cited by 200
Xu, X. Y., Huang, W. C., Heczey, A. A., Liu, D., Guo, L., Wood, M. S., Jin, J., Courtney, A. N., Liu, B., Pierro, E. J. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0421 · Cited by 200
Myers, R. M., Li, Y., Leahy, A. B., Barrett, D. M., Teachey, D. T., Callahan, C. A., Fasano, C., Rheingold, S. R., DiNofia, A. M., Wray, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03458 · Cited by 194
Research progress on dendritic cell vaccines in cancer immunotherapy
Yu, J., Sun, H., Cao, W., Song, Y., & Jiang, Z. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00257-2 · Cited by 194
Drent, E., Poels, R., Ruiter, R. W. J., van de Donk, N. W. C. J., Zweegman, S., Yuan, H., de Bruijn, J. D., Sadelain, M., Lokhorst, H. M., Groen, R. W. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2559 · Cited by 195
Yang, M., Tang, X., Zhang, Z., Gu, L., Heng, W., Zhao, S., Zhong, K., Mu, M., Huang, C., Jiang, C., et al. (2020) · Theranostics · doi:10.7150/thno.43991 · Cited by 192
HLA-independent T cell receptors for targeting tumors with low antigen density
Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01621-1 · Cited by 190
Png, Y. T., Vinanica, N., Kamiya, T., Shimasaki, N., Coustan‐Smith, E., & Campana, D. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009928 · Cited by 192
Pollmann, R., Schmidt, T., Eming, R., & Hertl, M. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8662-z · Cited by 189
Grigor, E., Fergusson, D. A., Kekre, N. K., Montroy, J. R., Atkins, H. L., Seftel, M. D., Daugaard, M., Presseau, J., Thavorn, K., Hutton, B., et al. (2019) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2019.01.005 · Cited by 191
Ruella, M., Kenderian, S. S., Shestova, O. E., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nuñez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 190
Lehmberg, K., Nichols, K. E., Henter, J., Girschikofsky, M., Greenwood, T. V. B., Jordan, M. B., Kumar, A. R., Minkov, M., Rosée, P. G. L., & Weitzman, S. S. (2015) · Haematologica · doi:10.3324/haematol.2015.123562 · Cited by 188
CAR models: next-generation CAR modifications for enhanced T-cell function
Abate‐Daga, D., & Davila, M. L. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.14 · Cited by 194
Oelsner, S., Friede, M. E., Zhang, C., Wagner, J., Badura, S., Bader, P., Ullrich, E., Ottmann, O. G., Klingemann, H., Tonn, T., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.10.009 · Cited by 188
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 185
Nanobody: a promising toolkit for molecular imaging and disease therapy
Bao, G., Tang, M., Zhao, J., & Zhu, X. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00750-5 · Cited by 197
Metadata
- Authors
- Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- University of Nevada, Reno (US)
- University of Southern California (US)
- Corresponding author
- Mackall, Crystal L
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 385
- Issue
- 9967
- Pages
- 517-528
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7065359
- OpenAlex
- W2129702476
- Cited by
- 2,898
- References
- 37
- Citations by year
- 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
- FWCI
- 103.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. Baldrick's Foundation
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
